Receptor tyrosine kinase inhibitors as anti-angiogenic agents

Dong Wook Kim, Bo Lu, Dennis E. Hallahan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Receptor tyrosine kinases (RTKs) and their ligands have been implicated in angiogenesis and current data suggest that they are potential cancer therapeutic targets. Split-kinase domain RTKs, including receptors for vascular endothelial growth factor receptor, platelet-derived growth factor and fibroblast growth factor, have important roles in tumor angiogenesis. RTK inhibitors targeting tumor microvasculature have shown promising results in preclinical studies, and use of these compounds as single agents, or in combination with other cytotoxic therapies, including radiation, is an area of active clinical investigation. Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.

Original languageEnglish (US)
Pages (from-to)597-604
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume5
Issue number6
StatePublished - Jun 2004

Fingerprint

Receptor Protein-Tyrosine Kinases
Neoplasms
Vascular Endothelial Growth Factor Receptor
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Microvessels
Phosphotransferases
Radiotherapy
Ligands
Therapeutics

Keywords

  • Angiogenesis
  • Cancer
  • Radiation
  • Receptor tyrosine kinase
  • SU-11248
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Receptor tyrosine kinase inhibitors as anti-angiogenic agents. / Kim, Dong Wook; Lu, Bo; Hallahan, Dennis E.

In: Current Opinion in Investigational Drugs, Vol. 5, No. 6, 06.2004, p. 597-604.

Research output: Contribution to journalArticle

Kim, DW, Lu, B & Hallahan, DE 2004, 'Receptor tyrosine kinase inhibitors as anti-angiogenic agents', Current Opinion in Investigational Drugs, vol. 5, no. 6, pp. 597-604.
Kim, Dong Wook ; Lu, Bo ; Hallahan, Dennis E. / Receptor tyrosine kinase inhibitors as anti-angiogenic agents. In: Current Opinion in Investigational Drugs. 2004 ; Vol. 5, No. 6. pp. 597-604.
@article{64f039b134c24576ae7e2df76ebd0e89,
title = "Receptor tyrosine kinase inhibitors as anti-angiogenic agents",
abstract = "Receptor tyrosine kinases (RTKs) and their ligands have been implicated in angiogenesis and current data suggest that they are potential cancer therapeutic targets. Split-kinase domain RTKs, including receptors for vascular endothelial growth factor receptor, platelet-derived growth factor and fibroblast growth factor, have important roles in tumor angiogenesis. RTK inhibitors targeting tumor microvasculature have shown promising results in preclinical studies, and use of these compounds as single agents, or in combination with other cytotoxic therapies, including radiation, is an area of active clinical investigation. Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.",
keywords = "Angiogenesis, Cancer, Radiation, Receptor tyrosine kinase, SU-11248, Vascular endothelial growth factor",
author = "Kim, {Dong Wook} and Bo Lu and Hallahan, {Dennis E.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "5",
pages = "597--604",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Receptor tyrosine kinase inhibitors as anti-angiogenic agents

AU - Kim, Dong Wook

AU - Lu, Bo

AU - Hallahan, Dennis E.

PY - 2004/6

Y1 - 2004/6

N2 - Receptor tyrosine kinases (RTKs) and their ligands have been implicated in angiogenesis and current data suggest that they are potential cancer therapeutic targets. Split-kinase domain RTKs, including receptors for vascular endothelial growth factor receptor, platelet-derived growth factor and fibroblast growth factor, have important roles in tumor angiogenesis. RTK inhibitors targeting tumor microvasculature have shown promising results in preclinical studies, and use of these compounds as single agents, or in combination with other cytotoxic therapies, including radiation, is an area of active clinical investigation. Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.

AB - Receptor tyrosine kinases (RTKs) and their ligands have been implicated in angiogenesis and current data suggest that they are potential cancer therapeutic targets. Split-kinase domain RTKs, including receptors for vascular endothelial growth factor receptor, platelet-derived growth factor and fibroblast growth factor, have important roles in tumor angiogenesis. RTK inhibitors targeting tumor microvasculature have shown promising results in preclinical studies, and use of these compounds as single agents, or in combination with other cytotoxic therapies, including radiation, is an area of active clinical investigation. Preclinical and clinical data from representative anti-angiogenic RTK inhibitors will be discussed in this review.

KW - Angiogenesis

KW - Cancer

KW - Radiation

KW - Receptor tyrosine kinase

KW - SU-11248

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=4043130417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043130417&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 597

EP - 604

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -